REGENERON Trademark

Trademark Overview

On Thursday, October 15, 2020, a trademark application was filed for REGENERON with the United States Patent and Trademark Office. The USPTO has given the REGENERON trademark a serial number of 90256584. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, August 29, 2023. This trademark is owned by Regeneron Pharmaceuticals, Inc.. The REGENERON trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treatment of musculoskeletal, bone, and connective tissue diseases and disorders
regeneron

General Information

Serial Number90256584
Word MarkREGENERON
Filing DateThursday, October 15, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, August 29, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 26, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for treatment of musculoskeletal, bone, and connective tissue diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 3, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRegeneron Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591
Party NameRegeneron Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591

Trademark Events

Event DateEvent Description
Wednesday, August 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 29, 2023SOU EXTENSION 5 GRANTED
Wednesday, August 23, 2023SOU EXTENSION 5 FILED
Tuesday, August 29, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 23, 2023SOU TEAS EXTENSION RECEIVED
Saturday, February 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 16, 2023SOU EXTENSION 4 GRANTED
Thursday, February 16, 2023SOU EXTENSION 4 FILED
Thursday, February 16, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, September 6, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 2, 2022SOU EXTENSION 3 GRANTED
Friday, September 2, 2022SOU EXTENSION 3 FILED
Friday, September 2, 2022SOU TEAS EXTENSION RECEIVED
Thursday, July 14, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 14, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 14, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 23, 2022SOU EXTENSION 2 GRANTED
Wednesday, February 23, 2022SOU EXTENSION 2 FILED
Wednesday, February 23, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, August 25, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 23, 2021SOU EXTENSION 1 GRANTED
Monday, August 23, 2021SOU EXTENSION 1 FILED
Monday, August 23, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, March 23, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 26, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 26, 2021PUBLISHED FOR OPPOSITION
Wednesday, January 6, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 22, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 22, 2020ASSIGNED TO EXAMINER
Thursday, December 3, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 19, 2020NEW APPLICATION ENTERED

Related Keywords

regeneron tissue diseases disorders connective bone preparations treatment musculoskeletal pharmaceutical